A double-blind, placebo controlled, crossover, ascending single dose safety tolerability, pharmacokinetic and pharmacodynamic study of Neu-120 in patients with advanced phase idiopathic Parkinson's Disease with levodopa induced dyskinesia.

Trial Profile

A double-blind, placebo controlled, crossover, ascending single dose safety tolerability, pharmacokinetic and pharmacodynamic study of Neu-120 in patients with advanced phase idiopathic Parkinson's Disease with levodopa induced dyskinesia.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Neu 120 (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors NEURIM Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Apr 2014 Planned End Date changed from 1 Aug 2012 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Planned end date changed from 1 Aug 2008 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top